Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen wins quick EU approval for Imlygic, its first-in-class immuno-oncology drug
Amgen wins quick EU approval for Imlygic, its first-in-class immuno-oncology drug
Amgen wins quick EU approval for Imlygic, its first-in-class immuno-oncology drug
Submitted by
admin
on December 20, 2015 - 4:32pm
Source:
Fierce Pharma
News Tags:
Amgen
Europe
Imlygic
melanoma
Headline:
Amgen wins quick EU approval for Imlygic, its first-in-class immuno-oncology drug
Do Not Allow Advertisers to Use My Personal information
